Affinity for [3H]Iloprost binding sites and cAMP synthesis activity of a 3-oxa-methano prostaglandin I1 analog, SM-10906, in human platelets and endothelial cells

Japanese Journal of Pharmacology

Volumn 74, Issue 1, 1997, Pages 37-43

  Hiroi, Takashi ^a   Maruyama, Keiko ^a   Hattori, Kaoru ^a   Ohnuki, Toshio ^a   Nagatomo, Takafumi ^a   Watanabe, Kenichi ^b   Yamamoto, Takaaki ^c   Hara, Youichi ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b Department of Radiology   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cyclic AMP; Endothelial cell; Platelet; SM 10906; 3H Iloprost binding site

Indexed keywords

11,15 DIHYDROXY 17 METHYL 20 HOMO 6,9 METHANO 3 OXAPROST 13 ENOIC ACID; CYCLIC AMP; ILOPROST; PIMILPROST; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PROSTAGLANDIN E RECEPTOR; VASODILATOR AGENT;

ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NORMAL HUMAN; RECEPTOR AFFINITY; THROMBOCYTE; VEIN; ADULT; BINDING SITE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; IN VITRO STUDY; KINETICS; METABOLISM; MIDDLE AGED; RADIOASSAY; VASCULAR ENDOTHELIUM;

ADULT; ALPROSTADIL; BINDING SITES; BLOOD PLATELETS; CELLS, CULTURED; CYCLIC AMP; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; ILOPROST; KINETICS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RADIOLIGAND ASSAY; RECEPTORS, PROSTAGLANDIN E; VASODILATOR AGENTS;

EID: 0030610990     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.37     Document Type: Article

References (38)

1. 1 on the terminal vascular bed. Am J Physiol 217, 563-566 (1969)
2. Moncada S, Gryglewski R, Bunting S and Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665 (1976)
3. Bunting S, Gryglewski R, Moncada S and Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12, 897-913 (1976)
4. 1 on platelet behavior in vitro and in vivo. Br Med J 2, 468-472 (1967)
5. 3H]prostacyclin on platelets. J Clin Invest 63, 215-220 (1979)
6. MacDermot J, Blair IA and Cresp TM: Prostacyclin receptors of a neuronal hybrid cell line: divalent cations and ligand-receptor coupling. Biochem Pharmacol 30, 2041-2044 (1981)
7. Shepherd GL, MacDermot J, Blair IA and Lewis PJ: Prostacyclin receptors on human platelets. Clin Sci (Medical Research Society) 61, 29p (1981)
8. Rucker W and Schror K: Evidence for high affinity prostacyclin binding sites in vascular tissue: Radioligand studies with a chemistry stable analogue. Biochem Pharmacol 32, 2405-2410 (1983)
9. 1 in severe peripheral vascular disease. Lancet 1, 155-156 (1973)
10. 1 in severe peripheral vascular disease. Lancet 2, 810 (1976)
11. Kahan A, Weber S, Amor B and Menkes CJ: Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1, 538 (1983)
12. Coleman RA, Smith WL and Narumiya S: Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46, 205-229 (1994)
13. 2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 74, 3922-3926 (1977)
14. 2) in aqueous solutions. Prostaglandins 15, 943-954 (1978)
15. 1. Arzneimittelforschung 44, 483-490 (1994)
16. ++ increase in rat platelets stimulated by thrombin. Thromb Res 79, 307-317 (1995)
17. Oka M, Negishi M, Yamamoto T, Satoh K, Hirohashi T and Ichikawa A: Prostacyclin (PGI) receptor binding and cyclic AMP synthesis activities of PGI, analogues, SM-10906 and its methyl ester, SM-10902, in mastocytoma P-815 cells. Biol Pharm Bull 17, 74-77 (1994)
18. Yamamoto T, Horikawa N, Komuro Y and Hara Y: Effect of topical application of a stable prostacyclin analogue, SM-10902 on wound healing in diabetic mice. Eur J Pharmacol 302, 53-60 (1996)
19. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275 (1951)
20. Tsai A-L, Vijjeswarapu H and Wu KK: Interaction between platelet receptor and iloprost isomers. Biochim Biophy Acta 942, 220-226 (1988)
21. Tsai A-L, Hsu M-J, Vijjeswarapu H and Wu KK: Solubilization of prostacyclin membrane receptors from human platelets. J Biol Chem 264, 61-67 (1989)
22. 2 on human gel-filtered platelets. J Pharmacol Exp Ther 236, 568-573 (1986)
23. Mizuno Y, Ichikawa A and Tomita K: Effect of 7-fluoro prostacyclin, a stable prostacyclin analogue, on cAMP accumulation and prostaglandin binding in mastocytoma P-815 cells. Prostaglandins 26, 785-795 (1983)
24. 1/prostacyclin receptor of human blood platelets. J Biol Chem 262, 12685-12691 (1987)
25. Negishi M, Hashimoto H, Yatsunami K, Kurozumi S and Ichikawa A: TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells. Prostaglandins 42, 225-237 (1991)
26. Johnson AR, Cambell W, Davis L and Schulz W: Influence of prostacyclin on endothelial cell injury (abstract). Fed Proc 42, 772 (1983)
27. Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE and Gasic GP: Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200, 52-54 (1978)
28. Konturek SJ and Robert A: Cytoprotection of canine gastric mucosa by prostacyclin: Possible mediation by increased mucosal blood flow. Digestion 25, 155-163 (1982)
29. Blackwell GJ, Radomski M, Vargas JR and Moncada S: Prostacyclin prolongs viability of washed human platelets. Biochim Biophys Acta 718, 60-65 (1982)
30. 2 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 113, 506-512 (1983)
31. Renkawek K, Herbaczynska CK and Mossakowski MJ: The effect of prostacyclin on morphological and enzymatic properties of CNS cultures exposed to anoxia. Acta Neurol Scand 73, 111-118 (1986)
32. Yamamoto T and Hara Y: The protective action of a stable prostacyclin analogue, SM-10906 on cultured human umbilical endothelial cells. Jpn Pharmacol Ther 24, 789-794 (1996) (Abstr in English)
33. Sakai A, Yajima M and Nishio S: Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 47, 711-719 (1990)
34. Kainoh M, Maruyama I, Nishio S and Nakadate T: Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cAMP level. Biochem Pharmacol 41, 1135-1140 (1991)
35. Kainoh M, Nishio S and Nakadate T: Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells. Pharmacology 45, 61-70 (1992)
36. 2 production by rat blood vessels: diminished prostacyclin formation in veins compared to arteries. Prostaglandins 16, 1-16 (1978)
37. Schröder H and Schrör K: Prostacyclin-dependent cyclic AMP formation in endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 347, 101-104 (1993)
38. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A and Narumiya S: In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116, 2828-2837 (1995)